Work

Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes

Year: 2015

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v126.23.1669.1669

Authors: David Valcarcel, Amit Verma, Uwe Platzbecker, Valeria Santini, Aristoteles Giagounidis, María Díez-Campelo, Jan Janssen, Richard F. Schlenk, Gianluca Gaidano, Jaime Perez de Oteyza, Ann L Cleverly, Alan Y Chiang, Michael Lahn, Durisala Desiaih, Susan C. Guba, Alan F. List, Rami S. Komrokji

Institutions: Vall d'Hebron Hospital Universitari, Albert Einstein College of Medicine, University Hospital Carl Gustav Carus, University of Florence, Marien Hospital Düsseldorf, University Hospital Ulm, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Hospital Universitario Ramón y Cajal, Eli Lilly (United Kingdom), Eli Lilly (United States), Moffitt Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2505939651

FWCI: 2.35

Cites:

Cited by: 20

Related to: 10